On April 18, 2017 Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, reported that the Company will present new preclinical data on SY-1425, its oral first-in-class selective retinoic acid receptor alpha (RARα) agonist currently in a Phase 2 clinical trial in genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (Press release, Syros Pharmaceuticals, APR 19, 2017, View Source [SID1234518617]). These data were selected for oral presentation during a plenary session at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Hematologic Malignancies: Translating Discoveries to Novel Therapies conference taking place from May 6-9 in Boston. Schedule your 30 min Free 1stOncology Demo! Details on the plenary talk and corresponding poster presentation are as follows:
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Title: SY-1425 (tamibarotene), a potent and selective RARα agonist, induces changes in the transcriptional regulatory circuit of AML cells leading to differentiation
Presenter: Christopher Fiore, Ph.D., Scientist, Syros Pharmaceuticals
Date & Time of Plenary Session: Sunday, May 7, from 10:30 a.m. – 1 p.m.
Plenary Session 3: Chemical Biology
Location: Westin Boston Waterfront, Harbor Ballroom 3
Date & Time of Poster Presentation: Sunday, May 7, from 1 – 3 p.m.
Location: Westin Boston Waterfront, Harbor Ballroom 1-2, Poster Board Number 06